<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02926846</url>
  </required_header>
  <id_info>
    <org_study_id>2013.201</org_study_id>
    <nct_id>NCT02926846</nct_id>
  </id_info>
  <brief_title>IV Antibiotics With Lavage for Severe PD Peritonitis</brief_title>
  <official_title>Randomized Trial on Intravenous Antibiotics With Adjunctive Lavage for Severe Peritoneal-dialysis Related Peritonitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alice Ho Miu Ling Nethersole Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alice Ho Miu Ling Nethersole Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized controlled trial to evaluate whether a switch to intravenous antibiotics
      with adjunctive lavage can improve the outcome of severe peritoneal dialysis related
      peritonitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The standard treatment of peritoneal dialysis (PD) related peritonitis is intraperitoneal
      (IP) antibiotics. In severe cases not responding to the IP antibiotics treatment, timely
      Tenckhoff catheter removal is needed. There is no known adjunctive measure that can improve
      the clinical outcome of the patients suffering from severe PD peritonitis.

      Based on the past experience in the investigators' center, switching IP to intravenous route
      of antibiotics administration, together with adjunctive lavage was proposed to improve the
      clinical outcome of severe PD peritonitis, in particular a possible improved catheter salvage
      rate. This method will be evaluated in the present clinical trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">January 2018</completion_date>
  <primary_completion_date type="Actual">November 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peritoneal dialysate effluent (PDE) white cell count and bacterial culture</measure>
    <time_frame>PDE is monitored every 48 hours, until white cell count &lt;100/mm3 and bacterial culture is negative; assessed up to 3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants requiring Tenckhoff catheter removal</measure>
    <time_frame>Tenckhoff catheter removal is arranged when there is no clinical response after 5 days of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants developing relapsing peritonitis</measure>
    <time_frame>All participants are observed for any peritonitis within 4 weeks of completion of antibiotics treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants requiring hospitalization</measure>
    <time_frame>All participants are observed for any hospitalization within 12 weeks of completion of antibiotics treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Peritonitis</condition>
  <condition>Kidney Failure</condition>
  <arm_group>
    <arm_group_label>Lavage arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous vancomycin &amp; gentamicin with adjunctive lavage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard treatment arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intraperitoneal vancomycin &amp; gentamicin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous vancomycin &amp; gentamicin with adjunctive lavage</intervention_name>
    <description>Intravenous vancomycin and gentamicin are administered, together with adjunctive lavage performed by automated peritoneal dialysis machine over 48 to 72 hours.
(choice of antibiotic is adjusted in accordance with the microbiology report when available)</description>
    <arm_group_label>Lavage arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intraperitoneal vancomycin &amp; gentamicin</intervention_name>
    <description>Intraperitoneal vancomycin and gentamicin are administered, with the usual continuous ambulatory peritoneal dialysis schedule maintained.
(choice of antibiotic is adjusted in accordance with the microbiology report when available)</description>
    <arm_group_label>Standard treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prevalent PD patients with age &gt;= 18 years old suffering from PD peritonitis

          -  PD effluent white cell count &gt;1090/mm2 on peritonitis day 3

          -  Lack of clinical response

          -  Informed consent available

        Exclusion Criteria:

          -  PD peritonitis in association with exit site or tunnel infection

          -  Relapsing peritonitis (i.e. peritonitis caused by same organism within 4 weeks after
             completion of antibiotics therapy)

          -  Fungal peritonitis

          -  Mycobacterial peritonitis (both tuberculosis and non-tuberculosis species)

          -  Clinical suspicion of surgical peritonitis

          -  Penicillin- or cephalosporin allergy, that cefazolin and ceftazidime could not be used
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Siu-Man Wong, MBChB, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alice Ho Miu Ling Nethersole Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alice Ho Miu Ling Nethersole Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2016</study_first_submitted>
  <study_first_submitted_qc>October 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2016</study_first_posted>
  <last_update_submitted>January 29, 2018</last_update_submitted>
  <last_update_submitted_qc>January 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Alice Ho Miu Ling Nethersole Hospital</investigator_affiliation>
    <investigator_full_name>Steve Siu-Man Wong</investigator_full_name>
    <investigator_title>Associate Consultant</investigator_title>
  </responsible_party>
  <keyword>Peritoneal dialysis</keyword>
  <keyword>Lavage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Peritonitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Gentamicins</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

